NRG1: An Emerging Tumor Agnostic Target

Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries a text-based module and a downloadable slideset.

Share

Program Content

Activities

<em>NRG1</em> Fusion&ndash;Positive Tumors: Module
Neuregulin-1 (NRG1): An Emerging Tumor-Agnostic Target
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2022

Expires: February 01, 2023

Activities

NRG1 Fusion–Positive Tumors: Slides
NRG1: An Emerging Tumor-Agnostic Target
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2022

Expires: February 01, 2023

Activities

Testing for NRG1-Driven Cancers
NRG1 Oncogenic Gene Fusions Across Solid Tumors: What You Should Know About Testing
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 16, 2021

Expires: November 15, 2022

Treatment of <em>NRG1</em>-Positive Cancers
NRG1 Oncogenic Gene Fusions Across Solid Tumors: Emerging New Agents for an Important Target
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 28, 2022

Expires: February 27, 2023

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Elevation Oncology

Partners

American Society for Clinical Pathology

ProCE Banner